Thursday, January 19

Time: 12:15 PM – 1:00 PM

Location: Posters, Exhibits, and Food Room

Title: Applications of personalized ctDNA testing to optimize treatment decisions in patients with GI cancers

Description: Please join our Industry Expert Theater as we take a closer look at the clinical utility of personalized ctDNA testing for molecular residual disease assessment to address some of the common challenges physicians face when managing their patients with GI cancer.

Company: Natera, Inc.

Presenter: Adham Jurdi, MD- Medical Director, Oncology


Time: 5:00 PM – 5:45 PM

Location: Posters, Exhibits, and Food Room

Title: Redefining Cancer Care: The Importance of Genomic Driven Oncology

Description: A genomic-driven approach to oncology is rapidly evolving. We will discuss the emerging science on genomic alterations, which includes both genetic mutations and pathogenic gene fusions; including NRG1. We will also discuss the benefits of comprehensive RNA-based NGS testing.

Company: Merus

Presenter: Dan Hennessy Vice President, Medical Affairs


Friday, January 20

Time: 12:15 PM – 1:00 PM

Location: Posters, Exhibits, and Food Room

Title: Expanding Treatment Approaches for Unresectable Hepatocellular Carcinoma and Locally Advanced or Metastatic Biliary Tract Cancer

Description: An overview of hepatobiliary cancers followed by summaries of data from the HIMALAYA study of IMFINZI + IMJUDO in unresectable hepatocellular carcinoma and the TOPAZ-1 study of IMFINZI + gemcitabine/cisplatin in locally advanced and metastatic biliary tract cancer.

Company: AstraZeneca

Presenter: Stephen Valerio, US Medical Lead – IO


Time: 4:45 PM – 5:30 PM

Location: Posters, Exhibits, and Food Room

Title: PEMAZYRE (pemigatinib): The First FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with an FGFR2 Fusion or Rearrangement

Description: Hear Dr. Susan Snodgrass of Incyte present key data from the FIGHT-202 study, a trial evaluating the use of PEMAZYRE in cholangiocarcinoma patients with FGFR2 fusions or rearrangements

Company: Incyte Corporation

Presenter: Susan Snodgrass, MD – Vice President, US Medical Affairs


For more information: